



Clinical trial results:

A randomized, placebo-controlled, double-blind, parallel-group, multicenter Phase 2a study to investigate efficacy and safety of zabedoserib (BAY 1834845) for the treatment of adult patients with moderate-to-severe atopic dermatitis

Summary

EudraCT number	2022-000520-38
Trial protocol	CZ FR IT PL
Global end of trial date	28 February 2024

Results information

Result version number	v1 (current)
This version publication date	05 March 2025
First version publication date	05 March 2025

Trial information

Trial identification

Sponsor protocol code	BAY1834845/22158
-----------------------	------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05656911
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 February 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	28 February 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of zabedoseritib vs. placebo in adult patients with moderate-to-severe atopic dermatitis (AD) with inadequate response to topical corticosteroids or if topical treatments are medically not advisable.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects (or their legally authorized representative according to local legislation). Participating subjects (or their legally authorized representative according to local legislation) signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy:

All subjects had to use a stable amount of emollient as background therapy during the course of the study.

Evidence for comparator: -

Actual start date of recruitment	21 December 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	United States: 5
Country: Number of subjects enrolled	Poland: 14
Country: Number of subjects enrolled	Czechia: 30
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Germany: 8
Country: Number of subjects enrolled	Italy: 8
Worldwide total number of subjects	77
EEA total number of subjects	67

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	77
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study was conducted at 22 centers in Europe and US between 21-DEC-2022 (first subject first visit) and 31-JAN-2024 (last subject last visit).

Pre-assignment

Screening details:

A total of 129 subjects were screened in this study. Of those, 52 did not pass screening (44 were screened failures, 1 was physician decision, 6 were subject decision, 1 was other reasons). A total of 77 subjects were randomized.

Period 1

Period 1 title	Treatment phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Zabedoseritib (BAY1834845)

Arm description:

Subjects received zabedoseritib for up to 12 weeks (84 days).

Arm type	Experimental
Investigational medicinal product name	Zabedoseritib
Investigational medicinal product code	BAY1834845
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

120 mg, oral administration, two times a day

Arm title	Placebo
------------------	---------

Arm description:

Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days).

Arm type	Placebo
Investigational medicinal product name	Matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

oral administration, two times a day

Number of subjects in period 1	Zabedoseritib (BAY1834845)	Placebo
Started	52	25
Completed	36	19
Not completed	16	6
Physician decision	2	-
Subject Decision	4	2
Adverse event, non-fatal	3	1
Other Reasons	1	-
Lack of efficacy	6	3

Period 2

Period 2 title	Follow-up phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Zabedoseritib (BAY1834845)

Arm description:

Subjects received zabedoseritib for up to 12 weeks (84 days).

Arm type	Experimental
Investigational medicinal product name	Zabedoseritib
Investigational medicinal product code	BAY1834845
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

120 mg, oral administration, two times a day

Arm title	Placebo
------------------	---------

Arm description:

Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days).

Arm type	Placebo
Investigational medicinal product name	Matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

oral administration, two times a day

Number of subjects in period 2	Zabedoseritib (BAY1834845)	Placebo
Started	36	19
Completed	35	18
Not completed	1	1
Subject Decision	-	1
Missing	1	-

Baseline characteristics

Reporting groups

Reporting group title	Zabedoseritib (BAY1834845)
Reporting group description: Subjects received zabedoseritib for up to 12 weeks (84 days).	
Reporting group title	Placebo
Reporting group description: Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days).	

Reporting group values	Zabedoseritib (BAY1834845)	Placebo	Total
Number of subjects	52	25	77
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	35.2	32.9	
standard deviation	± 11.3	± 10.3	-
Gender categorical Units: Subjects			
Female	26	7	33
Male	26	18	44
Race Units: Subjects			
White	47	22	69
Black or African American	1	2	3
Asian	4	1	5
Ethnicity Units: Subjects			
Not Hispanic or Latino	50	24	74
Hispanic or Latino	2	1	3

End points

End points reporting groups

Reporting group title	Zabedoseritib (BAY1834845)
Reporting group description:	
Subjects received zabedoseritib for up to 12 weeks (84 days).	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days).	
Reporting group title	Zabedoseritib (BAY1834845)
Reporting group description:	
Subjects received zabedoseritib for up to 12 weeks (84 days).	
Reporting group title	Placebo
Reporting group description:	
Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days).	
Subject analysis set title	Per protocol set (PPS)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
All randomized subjects who: had an EASI score at baseline; had an EASI score at Day 56 (Visit 6) or later or took rescue medication between Day 56 (Visit 6) and Day 84 (Visit 7) or took standard of care or discontinued study intervention due to lack of efficacy (at any time); showed compliance of at least 80% with study intervention between start of treatment and end of treatment or start of rescue medication at or after Day 56 (Visit 6), whatever comes first; showed compliance of at least 80% with study intervention during the last 4 weeks before end of treatment or start of rescue medication at or after Day 56 (Visit 6), whatever comes first; without validity findings with respect to the efficacy related entry criteria.	
Subject analysis set title	Safety analysis set (SAF)
Subject analysis set type	Safety analysis
Subject analysis set description:	
All subjects who took at least 1 dose of study intervention.	

Primary: Achievement of 75% reduction from baseline in the Eczema Area and Severity Index (EASI 75 response) at Week 12 (Day 84)

End point title	Achievement of 75% reduction from baseline in the Eczema Area and Severity Index (EASI 75 response) at Week 12 (Day 84)
End point description:	
The endpoint was the composite variable defined as follows: - an EASI 75 response at Week 12 (Day 84), - no stop of study intervention for reasons related to lack of efficacy, - no rescue medication use during the 4 weeks before Day 84 and - no use of systemic atopic dermatitis (AD) treatment. The main estimand was the difference in the proportion of responders between treatment groups in adults with moderate-to-severe atopic dermatitis where use of topical rescue medication from Day 56 (Visit 6) onwards, use of systemic standard of care for AD and discontinuation of treatment due to lack of efficacy are handled as non-response (composite strategy). The estimand was regardless of use of rescue medication before Day 56 (Visit 6), regardless of non-compliance with emollients, and had treatment not been discontinued due to other reasons not related to lack of efficacy. Bayesian analysis according to estimand is presented.	
End point type	Primary
End point timeframe:	
Week 12 (Day 84)	

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[1]	22 ^[2]		
Units: Responder rate (percentage %)				
number (not applicable)	32.3	37.4		

Notes:

[1] - PPS

[2] - PPS

Statistical analyses

Statistical analysis title	Bayesian analysis according to estimand
----------------------------	---

Statistical analysis description:

Median of posterior distribution of difference between Zabedoseritib and Placebo including credible interval. Posterior probability is presented that the responder rate after treatment with zabedoseritib is higher than after placebo given the data observed in the study.

Comparison groups	Zabedoseritib (BAY1834845) v Placebo
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other ^[3]
Parameter estimate	Median difference (final values)
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29
upper limit	18

Notes:

[3] - Posterior probability is 34.0%.

Secondary: Percent change from baseline in EASI at Week 12 (Day 84)

End point title	Percent change from baseline in EASI at Week 12 (Day 84)
-----------------	--

End point description:

The EASI is a ClinRO assessing the extent of AD at four body regions by measuring the average severity of four clinical signs at each body region, each on a scale of 0 to 3. The minimum EASI score is 0 and the maximum EASI score is 72, with a higher score indicating worse severity of AD. The main estimand was based on the same strategies to address intercurrent events as described above for the primary endpoint. The mean difference between the treatment arms was used as summary measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 12 (Day 84)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[4]	22 ^[5]		
Units: percentage (%) of change				
least squares mean (confidence interval 95%)	-44.58 (-55.96 to -33.19)	-55.88 (-71.91 to -39.85)		

Notes:

[4] - PPS

[5] - PPS

Statistical analyses

Statistical analysis title	ANCOVA analysis
Statistical analysis description: The analysis of covariance (ANCOVA) model includes treatment group as fixed effect and the EASI baseline value as covariate.	
Comparison groups	Zabedoseritib (BAY1834845) v Placebo
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.257 ^[6]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	11.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.26
upper limit	30.87

Notes:

[6] - two-sided. No adjustment for multiple comparisons.

Secondary: Achievement of EASI 50 response at Week 12 (Day 84)

End point title	Achievement of EASI 50 response at Week 12 (Day 84)
End point description: The EASI is a ClinRO assessing the extent of AD at four body regions by measuring the average severity of four clinical signs at each body region, each on a scale of 0 to 3. The minimum EASI score is 0 and the maximum EASI score is 72, with a higher score indicating worse severity of AD. EASI 50 corresponds to the achievement of 50% reduction from baseline in EASI. The main estimand was calculated similarly as for EASI 75. Bayesian analysis according to estimand is presented.	
End point type	Secondary
End point timeframe: Week 12 (Day 84)	

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[7]	22 ^[8]		
Units: Responder rate (percentage %)				
number (not applicable)	52.7	55.4		

Notes:

[7] - PPS

[8] - PPS

Statistical analyses

Statistical analysis title	Bayesian analysis according to estimand
Statistical analysis description: Median of posterior distribution of difference between Zabedoseritib and Placebo including credible interval. Posterior probability is presented that the responder rate after treatment with zabedoseritib is higher than after placebo given the data observed in the study.	
Comparison groups	Zabedoseritib (BAY1834845) v Placebo
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other ^[9]
Parameter estimate	Median difference (final values)
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	22.1
Notes: [9] - Posterior probability is 41.7%.	

Secondary: Achievement of EASI 90 response at Week 12 (Day 84)

End point title	Achievement of EASI 90 response at Week 12 (Day 84)
End point description: The EASI is a ClinRO assessing the extent of AD at four body regions by measuring the average severity of four clinical signs at each body region, each on a scale of 0 to 3. The minimum EASI score is 0 and the maximum EASI score is 72, with a higher score indicating worse severity of AD. EASI 90 corresponds to the achievement of 90% reduction from baseline in EASI. The main estimand was calculated similarly as for EASI 75. Bayesian analysis according to estimand is presented.	
End point type	Secondary
End point timeframe: Week 12 (Day 84)	

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[10]	22 ^[11]		
Units: Responder rate (percentage %)				
number (not applicable)	15.6	20.4		

Notes:

[10] - PPS

[11] - PPS

Statistical analyses

Statistical analysis title	Bayesian analysis according to estimand
Statistical analysis description: Median of posterior distribution of difference between Zabedoseritib and Placebo including credible interval. Posterior probability is presented that the responder rate after treatment with zabedoseritib is higher than after placebo given the data observed in the study.	
Comparison groups	Zabedoseritib (BAY1834845) v Placebo

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other ^[12]
Parameter estimate	Median difference (final values)
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.6
upper limit	13.4

Notes:

[12] - Posterior probability is 31.5%.

Secondary: Achievement of a vIGA-AD response (score 0 or 1 and ≥ 2 points improvement) at Week 12 (Day 84)

End point title	Achievement of a vIGA-AD response (score 0 or 1 and ≥ 2 points improvement) at Week 12 (Day 84)
-----------------	--

End point description:

vIGA-AD stands for validated Investigator Global Assessment for Atopic Dermatitis. The vIGA-AD is a 1-item static ClinRO using a 5-point scale from 0 (clear) to 4 (severe) based on 4 clinical features of AD lesions: erythema, induration/papulation, lichenification, and oozing/crusting, and takes extent of disease into account. The main estimand was calculated similarly as for EASI 75. Bayesian analysis according to estimand is presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Day 84)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[13]	22 ^[14]		
Units: Responder rate (percentage %)				
number (not applicable)	15.9	28.5		

Notes:

[13] - PPS

[14] - PPS

Statistical analyses

Statistical analysis title	Bayesian analysis according to estimand
----------------------------	---

Statistical analysis description:

Median of posterior distribution of difference between Zabedoseritib and Placebo including credible interval. Posterior probability is presented that the responder rate after treatment with zabedoseritib is higher than after placebo given the data observed in the study.

Comparison groups	Zabedoseritib (BAY1834845) v Placebo
-------------------	--------------------------------------

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other ^[15]
Parameter estimate	Median difference (final values)
Point estimate	-12.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34.1
upper limit	7

Notes:

[15] - Posterior probability is 10.8%.

Secondary: Absolute change from baseline in body surface area (BSA) affected by atopic dermatitis (AD) at Week 12 (Day 84)

End point title	Absolute change from baseline in body surface area (BSA) affected by atopic dermatitis (AD) at Week 12 (Day 84)
-----------------	---

End point description:

BSA affected by AD was assessed for each section of the body, e.g. using the rule of nines. The possible highest score for each region is: Head and neck - 9%; Anterior trunk - 18%; Back - 18%; Upper limbs - 18%; Lower limbs - 36%; Genitals - 1%. Affected BSA was reported as a percentage of all major body sections combined. The main estimand was based on the same strategies to address intercurrent events as described above for the primary endpoint. The mean difference between the treatment arms was used as summary measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 12 (Day 84)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[16]	22 ^[17]		
Units: BSA (%)				
least squares mean (confidence interval 95%)	-13.28 (-18.98 to -7.58)	-20.34 (-28.60 to -12.07)		

Notes:

[16] - PPS

[17] - PPS

Statistical analyses

Statistical analysis title	ANCOVA analysis
----------------------------	-----------------

Statistical analysis description:

The analysis of covariance (ANCOVA) model includes treatment group as fixed effect and the EASI baseline value as covariate.

Comparison groups	Zabedoseritib (BAY1834845) v Placebo
-------------------	--------------------------------------

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.166 ^[18]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	7.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.92
upper limit	17.03

Notes:

[18] - two-sided. No adjustment for multiple comparisons.

Secondary: Achievement of a ≥ 4 point-improvement (reduction) in the weekly average of the Peak Pruritus 0-10 NRS score from baseline to Week 12 (Day 84) for subjects with Peak Pruritus 0-10 NRS score ≥ 4 at baseline

End point title	Achievement of a ≥ 4 point-improvement (reduction) in the weekly average of the Peak Pruritus 0-10 NRS score from baseline to Week 12 (Day 84) for subjects with Peak Pruritus 0-10 NRS score ≥ 4 at baseline
-----------------	---

End point description:

NRS stands for numerical rating scale. The Peak Pruritus 0-10 NRS is a single patient-reported item designed to measure peak pruritus (itch), or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable", how would you rate your itch at the worst moment during the previous 24 hours?'. ≥ 4 points reduction of the Peak Pruritus 0-10 NRS is considered a clinically relevant within-person response. NRS was assessed on a daily basis and the average over the last 7 days before the visit day was used for analysis. The main estimand was calculated similarly as for EASI 75. Bayesian analysis according to estimand is presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 12 (Day 84)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[19]	22 ^[20]		
Units: Responder rate (percentage %)				
number (not applicable)	16.4	25.0		

Notes:

[19] - PPS

[20] - PPS

Statistical analyses

Statistical analysis title	Bayesian analysis according to estimand
-----------------------------------	---

Statistical analysis description:

Median of posterior distribution of difference between Zabedoseritib and Placebo including credible interval. Posterior probability is presented that the responder rate after treatment with zabedoseritib is higher than after placebo given the data observed in the study.

Comparison groups	Zabedoseritib (BAY1834845) v Placebo
-------------------	--------------------------------------

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other ^[21]
Parameter estimate	Median difference (final values)
Point estimate	-8.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-30.4
upper limit	11

Notes:

[21] - Posterior probability is 20.5%.

Secondary: Absolute values of weekly average of the Peak Pruritus 0-10 numerical rating scale (NRS) score at Week 12 (Day 84)

End point title	Absolute values of weekly average of the Peak Pruritus 0-10 numerical rating scale (NRS) score at Week 12 (Day 84)
-----------------	--

End point description:

The Peak Pruritus 0-10 NRS is a single patient-reported item designed to measure peak pruritus (itch), or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable", how would you rate your itch at the worst moment during the previous 24 hours?'. ≥ 4 points reduction of the Peak Pruritus 0-10 NRS is considered a clinically relevant within-person response. NRS was assessed on a daily basis and the average over the last 7 days before the visit day was used for analysis. The main estimand was based on the same strategies to address intercurrent events as described above for the primary endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Day 84)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[22]	22 ^[23]		
Units: Scores on a scale				
arithmetic mean (standard deviation)	5.759 ($\pm$ 2.218)	5.36 ($\pm$ 2.311)		

Notes:

[22] - PPS

[23] - PPS

Statistical analyses

No statistical analyses for this end point

Secondary: Percent change of weekly average of the Peak Pruritus 0-10 NRS score from baseline at Week 12 (Day 84)

End point title	Percent change of weekly average of the Peak Pruritus 0-10 NRS score from baseline at Week 12 (Day 84)
-----------------	--

End point description:

The Peak Pruritus 0-10 NRS is a single patient-reported item designed to measure peak pruritus (itch), or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable", how would you rate your itch at the worst moment during the previous 24 hours?'. ≥ 4 points reduction of the Peak Pruritus 0-10 NRS is considered a

clinically relevant within-person response. NRS was assessed on a daily basis and the average over the last 7 days before the visit day was used for analysis. The main estimand was based on the same strategies to address intercurrent events as described above for the primary endpoint. ANCOVA analysis according to estimand is presented.

End point type	Secondary
End point timeframe:	
Baseline and Week 12 (Day 84)	

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	47 ^[24]	22 ^[25]		
Units: percentage of change (%)				
least squares mean (confidence interval 95%)	-20.65 (-29.54 to -11.77)	-27.33 (-40.00 to -14.66)		

Notes:

[24] - PPS

[25] - PPS

Statistical analyses

Statistical analysis title	ANCOVA analysis
----------------------------	-----------------

Statistical analysis description:

The analysis of covariance (ANCOVA) model includes treatment group as fixed effect and the EASI baseline value as covariate.

Comparison groups	Zabedoseritib (BAY1834845) v Placebo
Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.396 ^[26]
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	6.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.75
upper limit	22.11

Notes:

[26] - two-sided. No adjustment for multiple comparisons.

Secondary: Frequency and severity of treatment-emergent adverse events (TEAEs)

End point title	Frequency and severity of treatment-emergent adverse events (TEAEs)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From first treatment with the study intervention until 7 days after the last intake of study intervention (approximately up to 91 days)

End point values	Zabedoseritib (BAY1834845)	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52 ^[27]	25 ^[28]		
Units: Subjects				
Any AE	23	7		
Maximum intensity for any AE -MILD	13	4		
Maximum intensity for any AE - MODERATE	10	3		
Any SAE	0	0		
AE with outcome death	0	0		

Notes:

[27] - SAF

[28] - SAF

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events tables: from the start of study intervention until 7 days after the last intake (approximately up to 91 days). The deaths (all causes) considers all deaths that occurred at any time during the study before the last contact, up to 20 weeks.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	Zabedoseritib (BAY1834845)
-----------------------	----------------------------

Reporting group description:

Subjects received zabedoseritib for up to 12 weeks (84 days)

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received matching placebo to zabedoseritib for up to 12 weeks (84 days)

Serious adverse events	Zabedoseritib (BAY1834845)	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 52 (0.00%)	0 / 25 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Zabedoseritib (BAY1834845)	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 52 (44.23%)	7 / 25 (28.00%)	
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Surgical and medical procedures			
Gingival graft			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			

Pyrexia subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 25 (4.00%) 1	
Social circumstances Pregnancy of partner subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 25 (4.00%) 1	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Psychiatric disorders Depression subjects affected / exposed occurrences (all) Sleep disorder subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1 1 / 52 (1.92%) 1	0 / 25 (0.00%) 0 0 / 25 (0.00%) 0	
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	2 / 52 (3.85%) 2	0 / 25 (0.00%) 0	
Injury, poisoning and procedural complications Rib fracture subjects affected / exposed occurrences (all) Limb injury subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0 0 / 52 (0.00%) 0	1 / 25 (4.00%) 1 1 / 25 (4.00%) 1	
Cardiac disorders Sinus arrhythmia			

subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 25 (4.00%) 1	
Tachycardia subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Tremor subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Eye disorders Periorbital oedema subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Gastrointestinal disorders Vomiting subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Tongue oedema subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	2 / 52 (3.85%) 2	0 / 25 (0.00%) 0	
Palatal oedema subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Palatal swelling subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 25 (0.00%) 0	
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	2 / 52 (3.85%) 3	0 / 25 (0.00%) 0	
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	1 / 52 (1.92%)	1 / 25 (4.00%)	
occurrences (all)	1	1	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 52 (7.69%)	1 / 25 (4.00%)	
occurrences (all)	4	1	
Pustule			
subjects affected / exposed	1 / 52 (1.92%)	1 / 25 (4.00%)	
occurrences (all)	1	1	
Tonsillitis			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Hordeolum			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis viral			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 52 (0.00%)	1 / 25 (4.00%)	
occurrences (all)	0	1	
Urethritis			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Eczema impetiginous			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Viral infection			
subjects affected / exposed	1 / 52 (1.92%)	0 / 25 (0.00%)	
occurrences (all)	1	0	
Oral herpes			
subjects affected / exposed	0 / 52 (0.00%)	1 / 25 (4.00%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported